Evidence map›Paper›PMID 26946484›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2016

Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.

H Koppejan, L A Trouw, J Sokolove, L J Lahey, T J W Huizinga, I A Smolik, D B Robinson, H S El-Gabalawy, R E M Toes, C A Hitchon

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

H KoppejanLeiden University Medical Center, Leiden, The Netherlands.
L A TrouwLeiden University Medical Center, Leiden, The Netherlands.
J SokoloveStanford University School of Medicine, Stanford, California, and VA Palo Alto Health Care System, Palo Alto, California.
L J LaheyStanford University School of Medicine, Stanford, California, and VA Palo Alto Health Care System, Palo Alto, California.
T J W HuizingaLeiden University Medical Center, Leiden, The Netherlands.
I A SmolikUniversity of Manitoba, Winnipeg, Manitoba, Canada.
D B RobinsonUniversity of Manitoba, Winnipeg, Manitoba, Canada.
H S El-GabalawyUniversity of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-0796-4422
R E M ToesLeiden University Medical Center, Leiden, The Netherlands.
C A HitchonUniversity of Manitoba, Winnipeg, Manitoba, Canada.
Leiden University Medical Center · NLUniversity of Manitoba · CAVA Palo Alto Health Care System · US

Funding

CIHR MOP-77700
6 · The paper itself

Abstract

objectiveRheumatoid arthritis (RA) is characterized by the presence of autoantibodies, including seropositivity for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). In addition, antibodies to carbamylated proteins (anti-CarP) are present in patients with RA and are associated with joint damage. This study was undertaken to assess the presence of anti-CarP antibodies in indigenous North Americans (First Nations [FN] populations) with RA compared to their at-risk first-degree relatives (FDRs) and healthy controls.

methodsAnti-CarP IgG and ACPAs (specifically, anti-cyclic citrullinated peptide [anti-CCP] antibodies) were measured by enzyme-linked immunosorbent assay in the sera of FN patients with RA (n = 95), their unaffected FDRs (n = 109), and healthy FN controls (n = 85). Antibodies to additional citrullinated peptides were measured using a multiplex ACPA array, and the number of peptides recognized was reported as an ACPA score. Groups were compared using the chi-square test and Mann-Whitney U test. Associations between RA and seropositivity for RF, ACPAs, and anti-CarP antibodies were determined by logistic regression.

resultsAnti-CarP antibodies were more frequent in FN patients with RA (44.3%) compared to FDRs (18.3%) and FN controls (4.7%) (both P < 0.0001 versus RA). Moreover, anti-CarP antibodies were more frequent in FDRs than in FN controls (P = 0.008). The ACPA score was higher in anti-CCP-positive FN patients with RA than in anti-CCP-positive FN FDRs (median score 7 [interquartile range (IQR) 7] versus median score 1 [IQR 4]; P = 0.04). The association with RA was strongest when all 3 autoantibodies (RF, anti-CCP, and anti-CarP) were present in the patients' serum (odds ratio 194, 95% confidence interval 23-1,609, P < 0.0001).

conclusionAnti-CarP antibodies are prevalent in FN patients with RA and also more common in their at-risk FDRs compared to healthy controls. The results indicate an association of RF, ACPAs, and anti-CarP with RA that is strongest when all 3 autoantibodies are present. These findings may provide new insights into the evolution of autoimmunity in preclinical RA.

Indexed as

AdultArthritis, RheumatoidAutoantibodiesCitrullineFemaleHumansIndians, North AmericanMaleMiddle AgedPeptides, CyclicRheumatoid FactorAutoantibodiesCitrullinecyclic citrullinated peptidehomocitrullinePeptides, CyclicRheumatoid Factor

Identifiers

PMID26946484
PMCPMC6680251
OpenAlexW2509621774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.